Ji Hyun Park1,2, Hee Jin Lee3, Sae Byul Lee4, Jin-Hee Ahn2, Jeong Eun Kim2, Kyung Hae Jung2, Gyungyub Gong3, Byung-Ho Son4, Sei-Hyun Ahn4, Sung-Bae Kim5. 1. Department of Hemato-Oncology, Konkuk University Medical Center, Univeristy of Konkuk College of Medicine, Seoul, Republic of Korea. 2. Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea. 3. Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea. 4. Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea. 5. Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea sbkim3@amc.seoul.kr.
Abstract
BACKGROUND: The prognostic value of tumor-infiltrating lymphocytes (TILs) in curatively resected, but systemically untreated early-stage triple-negative breast cancer (TNBC) was investigated. MATERIALS AND METHODS: Patients with systemically untreated early TNBC between 1999 and 2012 were retrospectively reviewed. A low TIL level was defined as the presence of ≤10% stromal TILs Relapses were classified into locoregional and distant relapse. The primary endpoint was breast cancer-specific survival (BCSS). RESULTS: In 72 patients, the median TIL value was 10%, and low TIL status was found in 54.2%. Patients with pT1 and nodal-positive disease constituted 75% and 11.1%, respectively. With a median follow-up of 99 months, 26.4% patients experienced relapse; local in 63.2%, distant in 36.8%, and 9.7% died of disease progression. A low TIL level was significantly associated with distant relapse (p=0.013), and inferior 10-year BCSS, which was consistently observed in patients with T1a/b or N0 disease. CONCLUSION: A low TIL level seems to be an intrinsic prognostic factor in systemically untreated patients with early-stage TNBC, even in the T1a/bN0 subset. Copyright
BACKGROUND: The prognostic value of tumor-infiltrating lymphocytes (TILs) in curatively resected, but systemically untreated early-stage triple-negative breast cancer (TNBC) was investigated. MATERIALS AND METHODS:Patients with systemically untreated early TNBC between 1999 and 2012 were retrospectively reviewed. A low TIL level was defined as the presence of ≤10% stromal TILs Relapses were classified into locoregional and distant relapse. The primary endpoint was breast cancer-specific survival (BCSS). RESULTS: In 72 patients, the median TIL value was 10%, and low TIL status was found in 54.2%. Patients with pT1 and nodal-positive disease constituted 75% and 11.1%, respectively. With a median follow-up of 99 months, 26.4% patients experienced relapse; local in 63.2%, distant in 36.8%, and 9.7% died of disease progression. A low TIL level was significantly associated with distant relapse (p=0.013), and inferior 10-year BCSS, which was consistently observed in patients with T1a/b or N0 disease. CONCLUSION: A low TIL level seems to be an intrinsic prognostic factor in systemically untreated patients with early-stage TNBC, even in the T1a/bN0 subset. Copyright
Authors: Nour Abuhadra; Ryan Sun; Jennifer K Litton; Gaiane M Rauch; Clinton Yam; Jeffrey T Chang; Sahil Seth; Roland Bassett; Bora Lim; Alastair M Thompson; Elizabeth Mittendorf; Beatriz E Adrada; Senthil Damodaran; Jason White; Elizabeth Ravenberg; Rosalind Candelaria; Banu Arun; Naoto T Ueno; Lumarie Santiago; Sadia Saleem; Sausan Abouharb; Rashmi K Murthy; Nuhad Ibrahim; Aysegul A Sahin; Vicente Valero; William Fraser Symmans; Debu Tripathy; Stacy Moulder; Lei Huo Journal: Cancers (Basel) Date: 2022-03-04 Impact factor: 6.639